Abbott issues US alert over troponin test
This article was originally published in Clinica
Abbott Diagnostics has issued a voluntary, US recall of its heart injury diagnostic test, Architect Stat Troponin-I. The Abbott Park, Illinois company received complaints concerning inconsistent or invalid test results, but is advising customers to continue use of the product with updated instructions for use (IFU), which are being distributed to clinical labs.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.